TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. AU - Torre, L. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Smyth, E. C. AU - Verheij, M. AU - Allum, W. AU - Cunningham, D. AU - Cervantes, A. PY - 2016 DA - 2016// TI - Arnold D; ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw350 DO - 10.1093/annonc/mdw350 ID - Smyth2016 ER - TY - JOUR PY - 2017 DA - 2017// TI - Japanese gastric cancer treatment guidelines 2014 (ver. 4) JO - Gastric Cancer VL - 20 UR - https://doi.org/10.1007/s10120-016-0622-4 DO - 10.1007/s10120-016-0622-4 ID - ref3 ER - TY - STD TI - National Comprehensive Cancer Network. Gastric cancer (version 2.2018). https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 15 Aug 2018. UR - https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf ID - ref4 ER - TY - JOUR AU - Kang, Y. K. AU - Boku, N. AU - Satoh, T. AU - Ryu, M. H. AU - Chao, Y. AU - Kato, K. PY - 2017 DA - 2017// TI - Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31827-5 DO - 10.1016/S0140-6736(17)31827-5 ID - Kang2017 ER - TY - JOUR AU - Fuchs, C. S. AU - Doi, T. AU - Jang, R. W. AU - Muro, K. AU - Satoh, T. AU - Machado, M. PY - 2018 DA - 2018// TI - Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.0013 DO - 10.1001/jamaoncol.2018.0013 ID - Fuchs2018 ER - TY - JOUR AU - Shitara, K. AU - Özgüroğlu, M. AU - Bang, Y. J. AU - Bartolomeo, M. AU - Mandalà, M. AU - Ryu, M. H. PY - 2018 DA - 2018// TI - Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)31257-1 DO - 10.1016/S0140-6736(18)31257-1 ID - Shitara2018 ER - TY - JOUR AU - Takahari, D. AU - Mizusawa, J. AU - Koizumi, W. AU - Hyodo, I. AU - Boku, N. PY - 2017 DA - 2017// TI - Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials JO - Gastric Cancer VL - 20 UR - https://doi.org/10.1007/s10120-017-0702-0 DO - 10.1007/s10120-017-0702-0 ID - Takahari2017 ER - TY - JOUR AU - Chau, I. AU - Norman, A. R. AU - Cunningham, D. AU - Waters, J. S. AU - Oates, J. AU - Ross, P. J. PY - 2004 DA - 2004// TI - Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized,Controlled Trials Using Individual Patient Data JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.08.154 DO - 10.1200/JCO.2004.08.154 ID - Chau2004 ER - TY - JOUR AU - McMillan, D. C. AU - Elahi, M. M. AU - Sattar, N. PY - 2001 DA - 2001// TI - Measurement of the systemic inflammatory response predicts cancer-specific and noncancersurvival in patients with cancer JO - Nutr Cancer VL - 41 UR - https://doi.org/10.1080/01635581.2001.9680613 DO - 10.1080/01635581.2001.9680613 ID - McMillan2001 ER - TY - JOUR AU - Spigel, D. R. AU - McCleod, M. AU - Jotte, R. M. AU - Einhorn, L. AU - Horn, L. AU - Waterhouse, D. M. PY - 2019 DA - 2019// TI - Safety, efficacy, and patient-reported health-related quality of life and symptom burden with Nivolumab in patients with advanced non-small cell lung Cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153) JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.05.010 DO - 10.1016/j.jtho.2019.05.010 ID - Spigel2019 ER - TY - JOUR AU - Mishima, S. AU - Kawazoe, A. AU - Nakamura, Y. AU - Sasaki, A. AU - Kotani, D. AU - Kuboki, Y. PY - 2019 DA - 2019// TI - Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0514-3 DO - 10.1186/s40425-019-0514-3 ID - Mishima2019 ER - TY - JOUR AU - Fujimoto, D. AU - Yoshioka, H. AU - Kataoka, Y. AU - Morimoto, T. AU - Kim, Y. H. AU - Tomii, K. PY - 2018 DA - 2018// TI - Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study JO - Lung Cancer VL - 119 UR - https://doi.org/10.1016/j.lungcan.2018.02.017 DO - 10.1016/j.lungcan.2018.02.017 ID - Fujimoto2018 ER - TY - JOUR AU - Katsura, H. AU - Suga, Y. AU - Araya, T. AU - Kita, T. AU - Yoneda, T. AU - Tanaka, N. PY - 2019 DA - 2019// TI - Efficacy and safety of Nivolumab in patients with advanced non-small-cell lung Cancer and poor performance status JO - J Cancer VL - 10 UR - https://doi.org/10.7150/jca.31217 DO - 10.7150/jca.31217 ID - Katsura2019 ER -